Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY (Details Textual)

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)		1 Months Ended		6 Months Ended		12 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Oct. 12, 2017	Jul. 31, 2018	Jul. 16, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Aug. 07, 2018	Sep. 12, 2017	Aug. 31, 2014
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,178,747
Common Stock, Shares Authorized				80,000,000		80,000,000
Proceeds from Warrant Exercises				$ 0	$ 2,940,759
Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.00
Convertible Preferred Stock, Shares Issued upon Conversion							176
Convertible Preferred Stock, Shares Issuable upon Conversion		2,785,000
Stockholders' Equity, Reverse Stock Split			At a special meeting held on July 12, 2018, our stockholders approved an amendment to our certificate of incorporation to affect a reverse split of our common stock at a ratio between 1:5 to 1:10 and authorized the Board to determine the ratio at which the reverse split would be. The Board authorized the ratio of the reverse split, and effective at the close of business on July 16, 2018, the Company implemented a 1-for-10 reverse stock split of its outstanding common stock. The accompanying condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock that the Company is authorized to issue remains unchanged at 80,000,000 and the par value remains at $0.00001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion						122,751
Conversion of Stock, Shares Converted						23
Preferred Stock Convertible Beneficial Conversion Feature				$ 1,448,945
Convertible Preferred Stock, Shares Issuable upon Conversion				96,283
October 2017 Registered public offering [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues	$ 7,760,000
October 2017 Registered public offering [Member] \| Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues	41.0412949
Shares Issued, Price Per Share	$ 100,000
Convertible Preferred Stock, Shares Issued upon Conversion	5,337
Convertible Preferred Stock, Total Number of Shares Issued upon Conversion	219,037
August 2014 Underwritten Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									970
Common Stock [Member]
Class of Warrant or Right [Line Items]
Common Stock, Shares Authorized						80,000,000		40,000,000
Common Stock [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues		1,355,000
Common Stock [Member] \| October 2017 Registered public offering [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues	195,438
Convertible Preferred Stock Conversion Price	$ 18.7375
Series D Warrants [Member] \| October 2017 Registered public offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	310,856
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 17.80
Stock Issued During Period On Exercise Of Warrants, Value	$ 7,800,000
Common Stock, Conversion Basis	0.75
Proceeds from Warrant Exercises	$ 7,100,000